Six times the demand for diet pills! The Nord and Nord growth story is just beginning?

As the dietary drugs spread around the world this year, pushing Danish pharmaceutical companies and Nord to take their first position in the European stock market, it finally took on a heavy weight of three quarters. According to the financial reports, Nord and Nord received DKK 166.4 billion (approximately DKK 17.29 billion) in the first nine months, an increase of 29 per cent in the same year and 33 per cent in the same exchange rate; the Māori rate reached 84.5 per cent; the operating profit was DKK 75.8 billion (DK 78.7 billion), an increase of 37 per cent in the same exchange rate; and the net profit was DKK 61.7 billion (DK 64.1 billion), an increase of 47 per cent.

Double-clicking on the original map and the greatest credit for this performance was the supply of the star products Ozempic and Wegovy. The first nine months of diabetes and obesity care operations under the Nord and Nord were DKK 15,3.8 billion, an increase of 36% over the same period (at the same rate of 40%), which was 92%. Of this, DKK 65.6 billion, an increase of 53% over the first nine months of Camp Ozepic, which was used primarily to treat diabetes, and DKK 21.7 billion for Wegovy, which increased at an alarming rate of 481% over the same period.